Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer
NCT04705649
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
42
Enrollment
OTHER
Sponsor class
Conditions
Endometrial Cancer
Interventions
OTHER:
Treatment de-escalation
Sponsor
British Columbia Cancer Agency